Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

WAVE LIFE SCIENCES LTD.

(WVE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
4.63(c) 4.69(c) 4.49(c) 4.39(c) 4.34(c) Last
262 860 165 406 476 853 387 382 147 967 Volume
-10.10% +1.30% -4.26% -2.23% -1.14% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 31,4 M - -
Net income 2021 -146 M - -
Net cash position 2021 94,3 M - -
P/E ratio 2021 -1,53x
Yield 2021 -
Sales 2022 40,5 M - -
Net income 2022 -141 M - -
Net cash position 2022 131 M - -
P/E ratio 2022 -1,94x
Yield 2022 -
Capitalization 220 M 220 M -
EV / Sales 2021 4,02x
EV / Sales 2022 2,21x
Nbr of Employees 219
Free-Float 95,3%
More Financials
Company
Wave Life Sciences Ltd. is a clinical-stage genetic medicines company engaged in delivering life-changing treatments for people battling devastating diseases. The Company is developing oligonucleotides, which targets ribonucleic acid (RNA) to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Using PRISM,... 
More about the company
Ratings of Wave Life Sciences Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about WAVE LIFE SCIENCES LTD.
10/22BB BIOTECH AG : BB Biotech: i ricavi -2-
DJ
10/22PRESS RELEASE : BB Biotech: Gains realized -2-
DJ
10/18WAVE LIFE SCIENCES : Takeda Pharmaceutical Partially Amend Central Nervous System Collabor..
MT
10/18WAVE LIFE SCIENCES : Takeda option to co-develop and co-commercialize late-stage CNS progr..
PU
10/18WAVE LIFE SCIENCES LTD. : Entry into a Material Definitive Agreement, Regulation FD Disclo..
AQ
10/18WAVE LIFE SCIENCES : and Takeda Amend CNS Collaboration
GL
09/29WAVE LIFE SCIENCES : Starts Dosing in Phase 1b/2a Clinical Trial of WVE-N531 in Duchenne M..
MT
09/29WAVE LIFE SCIENCES : Announces Initiation of Dosing in Phase 1b/2a Clinical Trial of WVE-N..
GL
09/29Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a Clinical Trial of WVE-..
GL
09/29Wave Life Sciences Ltd. Announces Initiation of Dosing in Phase 1b/2a Clinical Trial of..
CI
09/28WAVE LIFE SCIENCES LTD. : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
09/28Wave Life Sciences Announces New Data for Leading RNA Editing Capability Across Multipl..
GL
09/28Wave Life Sciences Announces New Data for Leading RNA Editing Capability Across Multipl..
CI
09/28WAVE LIFE SCIENCES : 2021 Analyst and Investor Research Webcast
PU
09/22Wave Life Sciences to Present at the Chardan Virtual Genetic Medicines Conference
GL
More news
News in other languages on WAVE LIFE SCIENCES LTD.
10/22BB BIOTECH : Gewinnrealisierungen -2-
10/18Wave Life Sciences et Takeda Pharmaceutical modifient partiellement l'accord de collabo..
09/09WAVE Life Sciences commence le dosage d'un essai de phase 1b/2a sur un médicament poten..
07/23DGAP-NEWS : Biotechbranche mit solidem 2. Quartal -2-
04/23DGAP-NEWS : BB BIOTECH AG: Erfolgreiche -2-
More news
Analyst Recommendations on WAVE LIFE SCIENCES LTD.
More recommendations
Chart WAVE LIFE SCIENCES LTD.
Duration : Period :
Wave Life Sciences Ltd. Technical Analysis Chart | WVE | SG9999014716 | MarketScreener
Technical analysis trends WAVE LIFE SCIENCES LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 4,34 $
Average target price 9,86 $
Spread / Average Target 127%
EPS Revisions
Managers and Directors
Paul B. Bolno President, Chief Executive Officer & Director
Kyle Moran Chief Financial & Accounting Officer
Christian O. Henry Chairman
Chandra Vargeese Chief Technology Officer
Michael Panzara Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
WAVE LIFE SCIENCES LTD.-44.85%220
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610